Struggling With Great Stock Picks? Discover StockInvest.us Top Gems!

Range Low Price High Price Comment
30 days $1.91 $2.42 Friday, 10th May 2024 CANF stock ended at $2.09. This is 2.42% less than the trading day before Thursday, 9th May 2024. During the day the stock fluctuated 3.29% from a day low at $2.05 to a day high of $2.12.
90 days $1.91 $2.71
52 weeks $1.81 $3.33

Historical Can-Fite BioPharma Ltd prices

Date Open High Low Close Volume
Jul 06, 2016 $2.23 $2.27 $2.18 $2.23 71 500
Jul 05, 2016 $2.09 $2.28 $2.01 $2.11 605 300
Jul 01, 2016 $2.61 $2.66 $2.53 $2.63 48 700
Jun 30, 2016 $2.55 $2.75 $2.55 $2.56 48 800
Jun 29, 2016 $2.63 $2.65 $2.52 $2.59 91 000
Jun 28, 2016 $2.65 $2.65 $2.50 $2.61 60 700
Jun 27, 2016 $2.57 $2.57 $2.51 $2.55 97 900
Jun 24, 2016 $2.56 $2.69 $2.56 $2.60 67 200
Jun 23, 2016 $2.70 $2.75 $2.66 $2.67 24 800
Jun 22, 2016 $2.78 $2.78 $2.66 $2.67 19 300
Jun 21, 2016 $2.62 $2.81 $2.60 $2.81 73 400
Jun 20, 2016 $2.65 $2.72 $2.64 $2.67 32 400
Jun 17, 2016 $2.75 $2.80 $2.60 $2.62 113 200
Jun 16, 2016 $2.65 $2.78 $2.62 $2.78 46 300
Jun 15, 2016 $2.88 $2.92 $2.61 $2.67 287 600
Jun 14, 2016 $2.72 $2.77 $2.50 $2.68 129 100
Jun 13, 2016 $2.74 $2.81 $2.72 $2.75 47 500
Jun 10, 2016 $2.87 $2.87 $2.71 $2.81 73 100
Jun 09, 2016 $2.90 $2.90 $2.85 $2.86 28 400
Jun 08, 2016 $2.91 $3.00 $2.82 $2.95 117 300
Jun 07, 2016 $2.95 $3.03 $2.88 $2.97 88 600
Jun 06, 2016 $3.10 $3.16 $2.95 $3.00 238 000
Jun 03, 2016 $2.86 $3.10 $2.85 $3.07 287 400
Jun 02, 2016 $2.96 $2.96 $2.84 $2.90 70 500
Jun 01, 2016 $2.96 $3.09 $2.76 $2.96 340 000
Click to get the best stock tips daily for free!

About Can-Fite BioPharma Ltd

Can-Fite BioPharma Ltd Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical tria... CANF Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT